‘Tis The Season… For An FDA Enforcement Letter To Alcon
This article was originally published in The Pink Sheet Daily
Executive Summary
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
You may also be interested in...
Nine Lives: Alcon’s Pataday Brochure Draws Yet Another FDA Letter
FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.
Jazz Buys Compliance Trouble With FazaClo Acquisition
The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.
Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.